🔧 This facility features small-scale bioreactors offering flexibility and cost efficiency.
💊 It aims to support innovative therapies, particularly for rare diseases, boosting production capabilities during product launches.
🚀 Lonza affirms its commitment to meeting market demand and providing industry-leading services.
Introduction:
The article discusses Lonza’s achievement in completing the first Good Manufacturing Practice (GMP) batch from its newly inaugurated next-generation mammalian manufacturing facility located in Portsmouth, New Hampshire. This facility marks a significant advancement in biomanufacturing capabilities aimed at meeting increasing market demands for drug production.
- Lonza’s new facility completed its first GMP product batch, enhancing their manufacturing capabilities for various biopharmaceuticals.
- The facility utilizes small-scale bioreactors, offering flexibility and cost-effectiveness in managing production volumes during product launches.
- Advancements in process analytical technology and optimized production processes aim to improve drug output quality and efficiency.
- The facility is designed to support small- to mid-volume products, particularly innovative therapies for rare diseases.
- This milestone reflects Lonza’s commitment to meet the evolving needs of customers throughout their product lifecycle while catering to growing market demand.
Conclusion:
Lonza’s completion of its first GMP batch at the new facility signifies a critical step in biomanufacturing, enhancing the company’s ability to support the development and production of novel therapies. The integration of advanced technologies and flexible production options positions Lonza well to address the diverse and evolving needs of the biopharmaceutical market, ultimately contributing to improved patient access to innovative treatments.
